Short answer
Sionna Therapeutics, Inc. (SION) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$20M
- −12.2% QoQ
- EPS (diluted)
- $978.57
- +371.8% QoQ
Source: XBRL data from the Sionna Therapeutics, Inc. (SION) Q3 2025 10-Q on SEC EDGAR. USD.
Sionna Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged from $0 YoY
- Net loss $20.3M vs $25.4M YoY; operating margin not applicable
- NBD1 and combination R&D highest program at $8.6M, up $2.8M YoY
- Cash, equivalents and marketable securities $325.0M at September 30, 2025
- Operating cash use $49.7M for nine months; IPO financing provided $204.1M
Risk Factors
- Newly triggered combination-therapy risk: SION-719 Phase 2a CF trial initiated in October 2025
- Clinical-stage losses: net loss $54.8 million and accumulated deficit $235.9 million through September 30, 2025
- Regulatory risk: FDA approval requirements may change during development and vary across jurisdictions
- Operational risk: SION-719 and SION-451 remain dependent on successful CF clinical trials
- Liquidity risk: $325.0 million cash, equivalents and marketable securities expected to fund operations into 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sionna Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.